CytoCore's New Bio-Marker to Be Presented at International Scientific Symposium.

CHICAGO -- CytoCore, Inc. (OTCBB:MCDG) chief research scientist and head of its Medical Advisory Board, Dr. George Gorodeski of University Hospitals Cleveland and Case Western University, will be presenting two papers on the unique apoptotic bio-maker Dr. Gorodeski discovered and licensed to CytoCore, the P2X7, at the 8th. International Symposium on Adenosine and Adenine Nucleotides in Ferrara Italy the last weekend in May: http://web.unife.it/convegni/8thadosymposium/

This Symposium held every 4 years attracts many of the world's top bio-molecular research scientists in the fields of Cellular Receptors, cancer bio-markers and ATP research.

Dr. Gorodeski stated, "We will be presenting two papers on the science behind the inactivation of the P2X7 by its truncated variant counter-part protein receptor, the P2X7-j, and how that relationship between the two appears to abrogate the P2X7 receptor's primary role in the apoptosis process. Because the effect was more prevalent in cancer cells, the inhibition of the apoptosis process may be an important mechanism for the enhancement of growth of cancer cells. This relationship between the paired receptors, the resulting decline in the apoptosis process, and the increase in cellular cancer growth has been found in the various types of epithelial cells that we have been studied so far. As a marker, the P2X7 has demonstrated very accurate sensitivity and specificity results in our initial testing for uterine epithelial cancers, including cervical and endometrial cancers. However, because of the widespread expression of the P2X7 receptor in epithelial tissues other the uterus, this mechanism may be more general than we initially thought. In fact, in one of the papers that we will present, we will also show a similar trend of results in skin and skin cancers. We are now conducting additional research to determine the possible role of the P2X7 as a general and effective screening marker for epithelial tissues."

About CytoCore Inc.

CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with a highly accurate, low-cost, cervical cancer screening and treatment system that can be integrated into existing medical models or at the point-of-care. More information is available at: www.Molecular-Dx.com

Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath(TM) System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2004 and its Quarterly Reports on Form 10-QSB for the quarters ended June 30, 2005 and September 30, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.